Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Feb. 8, 2021

Single-cell resolution reveals cell type, targets, for neuroblastoma

Feb. 8, 2021

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Feb. 8, 2021

Pfizer presents new TLR agonists

Feb. 8, 2021

Ono Pharmaceutical divulges KDM5A inhibitors

Feb. 8, 2021

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Feb. 5, 2021

CEACAM7 is a therapeutic target for CART therapy in PDAC

Feb. 5, 2021

University of South Australia discovers new candidate for glioblastoma

Feb. 5, 2021

New Aurora kinase inhibitors described by Wigen Biomedicine Technology

Feb. 5, 2021

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Feb. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...